BioTek’s Synergy H1 Receives HTRF Certification
News Sep 23, 2010
BioTek Instruments announces that their latest addition to the patent-pending Hybrid Microplate Reader family has received HTRF® certification from Cisbio Bioassays.
The Synergy™ H1 Hybrid Multi-Mode Microplate Reader is certified to meet or exceed strict performance and functional criteria for optimal HTRF results, which means that life science and drug discovery researchers are assured of increased productivity and extended flexibility for this assay platform.
Synergy H1 offers researchers a choice of monochromators or filters or both detection technologies in one compact unit. At its core, Synergy H1 is a monochromator-based multi-mode microplate reader with a quadruple grating architecture for robust performance and flexibility.
The optional HTRF-certified filter-based module may be added at any time to upgrade Synergy H1 to an advanced Hybrid system with broad current and future application range.
A dual-reagent injection system automates inject-and-read assays such as ion channel and flash luminescence assays, and Synergy H1 is compatible with BioTek’s Take3™ Multi-Volume Plate that measures up to sixteen 2 µL samples. Integrated Gen5™ Data Analysis Software provides advanced reader control, data analysis, graphing and reporting.
In addition to HTRF assays, Synergy H1 may be used for UV-Vis absorbance, top and bottom fluorescence, luminescence, fluorescence polarization, time-resolved fluorescence, FRET and BRET applications.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE